Tag
EPA: IPN
Mirum Pharmaceuticals reports LIVMARLI met Phase 3 EXPAND endpoint
Theo Marchetti · Oct 12, 2026
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP patients 12 and older
Adrian Kessler · Sep 26, 2026